Search - tctmd.com

Displaying 861 - 880 of 1554

Sort: Relevancy | Date

Presentation TCT 2018

Transcatheter Tricuspid Valve Therapies: Challenging Technologies and Clinical Trial Pathways

Presenter: Jaime Raben, Josep Rodés-Cabau

September 23, 2018

Presentation TCT 2018

SORT OUT IX: Summary and Clinical Implications

Presenter: Andreas Baumbach, Stephan Windecker, Lisette Okkels Jensen

September 23, 2018

Presentation TCT 2018

Most Frequent Errors I See in the Analysis and Interpretation of Trials

Presenter: Peter Juni, Robert W. Yeh

September 23, 2018

Presentation TCT 2018

How to Make Trials Larger, Simpler and Less Expensive

Presenter: Peter Juni, Robert W. Yeh, Matthew T. Roe

September 23, 2018

Presentation TCT 2018

LEADERS FREE II: Summary and Clinical Implications

Presenter: Andreas Baumbach, Stephan Windecker, Mitchell W. Krucoff

September 23, 2018

Presentation TCT 2018

Sham Controlled Trials for Devices Are Unethical, Unfeasible, and Unnecessary!

Presenter: Ajay J. Kirtane, Stuart J. Pocock, William F. Fearon

September 23, 2018

Presentation TCT 2018

Sham Controlled Trials Should Be the New Gold Standard for Device Trials!

Presenter: Ajay J. Kirtane, Stuart J. Pocock, Bernard J. Gersh

September 23, 2018

Presentation TCT 2018

ORBITA in the Spotlight: How I Would Have Done the Trial Differently

Presenter: Ajay J. Kirtane, Stuart J. Pocock

September 23, 2018

Presentation TCT 2018

ORBITA in the Spotlight: How I Interpret ORBITA as an Interventional Cardiologist

Presenter: Ajay J. Kirtane, Stuart J. Pocock, Rasha Al-Lamee

September 23, 2018

Presentation TCT 2018

All-Cause Mortality and Interpretation of Secondary Endpoints: The VEST and ODYSSEY Examples

Presenter: E. Magnus Ohman, Stuart J. Pocock

September 23, 2018

Presentation TCT 2018

What Are the Lasting Clinical Implications Of the ORBITA Trial?

Presenter: Anibal A. Damonte, Diego D Grinfeld, Alfredo E. Rodriguez, John A. Ambrose

September 23, 2018

Presentation TCT 2018

Patient Perspectives on Sham-Controlled Trials

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Debbe McCall

September 23, 2018

Presentation TCT 2018

FDA Perspectives on Sham-Controlled Trials

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Hiren Mistry

September 23, 2018

Presentation TCT 2018

ISCHEMIA Trial in the Spotlight: Why All the Fuss Over the Change in the Primary Endpoint?

Presenter: E. Magnus Ohman, Stuart J. Pocock, David J. Maron

September 23, 2018

Presentation TCT 2018

Composite Endpoints: When Are They Valid and When Should They Be Discarded

Presenter: E. Magnus Ohman, Stuart J. Pocock, Sanjay Kaul

September 23, 2018

Presentation TCT 2018

PADN-5: A Randomized Trial of Pulmonary Artery Denervation in Patients With Combined Pre- and Postcapillary Pulmonary Hypertension

Presenter: Valentin Fuster, Shao-Liang Chen

September 23, 2018

Presentation TCT 2018

Clinical Trial Considerations for Transcatheter TR Therapies

Presenter: Ori Ben-Yehuda

September 23, 2018

Presentation TCT 2018

Trialign Pioneering Work Technology and Clinical Updates

Presenter: Christopher U. Meduri

September 23, 2018

Presentation TCT 2018

ReCre8: Summary and Clinical Implications

Presenter: Sripal Bangalore, Lawrence A. Garcia, Pieter R. Stella

September 22, 2018

Presentation TCT 2018

TALENT: Summary and Clinical Implications

Presenter: Sripal Bangalore, Lawrence A. Garcia, Patrick W. Serruys

September 22, 2018

Advertisement

Transcatheter Tricuspid Valve Therapies: Challenging Technologies and Clinical Trial Pathways

SORT OUT IX: Summary and Clinical Implications

Most Frequent Errors I See in the Analysis and Interpretation of Trials

How to Make Trials Larger, Simpler and Less Expensive

LEADERS FREE II: Summary and Clinical Implications

Sham Controlled Trials for Devices Are Unethical, Unfeasible, and Unnecessary!

Sham Controlled Trials Should Be the New Gold Standard for Device Trials!

ORBITA in the Spotlight: How I Would Have Done the Trial Differently

ORBITA in the Spotlight: How I Interpret ORBITA as an Interventional Cardiologist

All-Cause Mortality and Interpretation of Secondary Endpoints: The VEST and ODYSSEY Examples

What Are the Lasting Clinical Implications Of the ORBITA Trial?

Patient Perspectives on Sham-Controlled Trials

FDA Perspectives on Sham-Controlled Trials

ISCHEMIA Trial in the Spotlight: Why All the Fuss Over the Change in the Primary Endpoint?

Composite Endpoints: When Are They Valid and When Should They Be Discarded

PADN-5: A Randomized Trial of Pulmonary Artery Denervation in Patients With Combined Pre- and Postcapillary Pulmonary Hypertension

Clinical Trial Considerations for Transcatheter TR Therapies

Trialign Pioneering Work Technology and Clinical Updates

ReCre8: Summary and Clinical Implications

TALENT: Summary and Clinical Implications

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content